Here's How Many Shares of AbbVie (ABBV) Stock You'd Need for $10,000 in Yearly Dividends

By Selena Maranjian – Mar 27, 2026 at 5:46AM ESTKey PointsAbbVie has increased its dividend by more than 330% since 2013.It has a robust pipeline of drugs in development and growing revenue, too.It's smart to seek dividend income from your investments because it can be used to help pay living expenses or to buy more stock. A solid dividend-paying stock to consider is pharmaceutical company AbbVie (ABBV +1.91%), which was spun off from Abbott Laboratories in 2013. The stock recently sported a 3.38% dividend yield, far above the average yield of 1.1% for stocks in the S&P 500. If you're looking for, say, $10,000 in annual dividend income, how many shares of AbbVie do you need to buy? Image source: Getty Images. Well, start by noting that the company's last quarterly dividend payment was $1.73 per share. The yearly run rate, then, is $6.92 per share. So divide $10,000 by $6.92, and you'll get 1,445 -- the number of shares you'd need. With the stock recently trading around $205 per share (as of March 24), those 1,445 shares would cost you a hefty $296,225. (Fortunately, you can always buy fewer than 1,445 shares!) ExpandNYSE: ABBVAbbVieToday's Change(1.91%) $3.96Current Price$211.14Key Data PointsMarket Cap$373BDay's Range$205.83 - $211.4252wk Range$164.39 - $244.81Volume103Avg Vol7.2MGross Margin70.12%Dividend Yield3.15% One reason to consider investing in AbbVie is that it's a rather reliable dividend payer -- and dividend grower. Since 2013, it has upped its payout by more than 330%. Better still, when you combine its history with that of Abbott Labs, you'll see that it has increased its payout annually for more than 25 years. So the $10,000 (or other sum) that you collect in dividends this year could be much more after a few years. The dividend is not the only reason to consider AbbVie. It's a strong grower in general, with its stock averaging annual gains of 16.2% over the past decade. Its 2025 revenue was up 8.6% over the year before -- despite its having lost patent protection for its blockbuster drug, Humira. Its pipeline of 90-plus drugs in development is promising, too. AbbVie's stock is reasonably priced, with a recent forward-looking price-to-earnings (P/E) ratio of 14, a bit above the five-year average of 13.Read NextMar 25, 2026 •By Keith SpeightsThe Fed Is Worried About Trump-Fueled Inflation.

Are Your Stocks Safe?Mar 24, 2026 •By Eric VolkmanWhat Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill.Mar 23, 2026 •By David Jagielski, CPAWhy AbbVie Stock Looks Like a Dirt Cheap Buy Right NowMar 17, 2026 •By Jason HallDividend Kings of 2026Mar 17, 2026 •By Patrick SandersMy Top 3 Dividend Kings to Buy for March 2026Mar 13, 2026 •By Matt DiLalloBests Bonds to Invest in for the Long Term (2026)About the AuthorSelena Maranjian is a contributing personal finance and investing expert at The Motley Fool. Selena has produced The Motley Fool’s nationally syndicated newspaper feature since 1997. She is the author of The Motley Fool Money Guide and Investment Clubs: How to Start and Run One the Motley Fool Way, and the co-author of The Motley Fool Investment Guide for Teens and several editions of The Motley Fool Investment Tax Guide. Prior to The Motley Fool, she worked as a high school teacher and public opinion analyst. She holds a master’s degree in teaching from Brown University and a master’s degree in finance from the Wharton School of the University of Pennsylvania.TMFSelenaStocks MentionedAbbVieNYSE: ABBV$211.14(+1.91%)+$3.96*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.